ArticleTherapeutic advances in chronic disease2012
Belimumab in systemic lupus erythematosus: an update for clinicians.
Article in Therapeutic advances in chronic disease, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.
- Belimumab for systemic lupus erythematosus.The Cochrane database of systematic reviews · 2021Pooled it
- Drug History and SLE Laboratory Findings Among Iraqi Patients: A Hospital-Based Study.Health science reports · 2025Article
- Platelet Dysfunction Diseases and Conditions: Clinical Implications and Considerations.Advances in therapy · 2020Review
- Depletion of PD-1-positive cells ameliorates autoimmune disease.Nature biomedical engineering · 2019Article
- Impact of belimumab on patient-reported outcomes in systemic lupus erythematosus: review of clinical studies.Patient related outcome measures · 2019Review
- Article
- TACI expression and signaling in chronic lymphocytic leukemia.Journal of immunology research · 2015Article
- Efficacy of novel monoclonal antibody belimumab in the treatment of lupus nephritis.Journal of pharmacology & pharmacotherapeuticsReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic lupus erythematosus (SLE) is a chronic inflammatory disorder that is driven by autoantibodies that target multiple organ systems. B-lymphocyte stimulator (BLyS) and its receptors on B-cell subsets play an important role in autoimmune B-cell development and SLE pathogenesis. Targeted therapy with belimumab, the monoclonal antibody against BLyS, has shown clinical benefit in two large-scale, multicenter phase III trials leading to US Food and Drug Administration approval for patients with serologically positive SLE who have active disease despite standard therapy. This review will discuss the challenges in lupus drug development and clinical trials, the basics of B-cell pathogenesis in SLE, the recent lupus clinical trials of B-cell targeted treatments, and other potential targeted therapies under investigation for patients with lupus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.